BeyondSpring shares Phase 2 lung cancer data showing survival benefit
BeyondSpring (NASDAQ:BYSI) announced updated data from an investigator-initiated Phase 2 clinical trial evaluating a triple-combination therapy for patients with advanced lung cancer, demonstrating sustained overall survival and disease control in a difficult-to-treat population.










